We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · April 20, 2021

AACR 2021: Addition of Ipilimumab to Adjuvant Nivolumab Did Not Improve Outcomes in Late-Stage Melanoma

The result may relate to a shorter treatment duration of the nivolumab-ipilimumab combination therapy

PracticeUpdate Editorial Team


Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading